Law360, New York (July 06, 2011, 1:51 PM ET) -- The European Commission closed its probe Wednesday into claims that Boehringer Ingelheim GmbH abused the patent system to corner the multibillion-dollar market for emphysema and related lung disease treatments after the German drugmaker settled with rival Almirall SA.
The four-year-old investigation stemmed from Almirall's complaint that in a bid to block its would-be competitor, Boehringer misled the European regulators in order to patent new treatments for chronic obstructive pulmonary disease based in part on a new active ingredient discovered by Barcelona-based Almirall.
At the urging of...
Boehringer Deal Leads EU Watchdog To Close Probe
To view the full article, take a free trial now.
